Skip to main content

Advertisement

SpringerLink
Log in

Organ Specific Tumor Markers: What’s New?

  • Review Article
  • Published:
Indian Journal of Clinical Biochemistry Aims and scope Submit manuscript

Abstract

Tumor markers are molecules produced in the body in response to cancer. An ideal tumor marker should have high sensitivity and specificity, should be cheap, and should be easily detected in body fluids. Identification of novel markers is important and it is expected that with the advent of newer technologies, more reliable markers will be discovered. This review discusses the currently available tumor markers for different malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Nair RR, Johnson JK. A dictionary to tumor markers and the methods of estimation. Advanced Biotech 2008; 22–32.

  2. Maugeri-Saccà M, De Maria R. Translating basic research in cancer patient care. Ann Ist Super Sanita. 2011;47(1):64–71. Review.

    PubMed  Google Scholar 

  3. Malati T. Tumour markers: an overview. Ind J Clin Biochem. 2007;22(2):17–31.

    Article  CAS  Google Scholar 

  4. Ishii M. Limitations of clinical usefulness of tumor marker. Gan To Kagaku Ryoho. 1995;22(9):1139–45. Review.

    PubMed  CAS  Google Scholar 

  5. Edge SB, et al., editors. AJCC cancer staging manual. New York: Springer; 2009.

    Google Scholar 

  6. Mostofi FK, Sesterhenn IA, Sobin LH. World Health Organization: International histological typing of tumors. 2nd edn ed. Berlin: Springer; 1998. p. 1–132.

    Google Scholar 

  7. Bhatt AN, Mathur R, Farooque A, Verma A, Dwarakanath BS. Cancer biomarkers—current perspectives. Indian J Med Res. 2010;132:129–49. Review.

    PubMed  CAS  Google Scholar 

  8. Ren J, Cai H, Li Y, Zhang X, Liu Z, Wang JS, et al. Tumor markers for early detection of ovarian cancer. Expert Rev Mol Diagn. 2010;10(6):787–98. Review.

    Article  PubMed  CAS  Google Scholar 

  9. Van Gorp T, Cadron I, Vergote I. The utility of proteomics in gynecologic cancers. Curr Opin Obstet Gynecol. 2011;23(1):3–7. Review.

    Article  PubMed  Google Scholar 

  10. Thankamani V, Kumari TV, Vasudevan DM. Detection of herpes simplex virus type-2 DNA and human papilloma virus DNA sequences in cervical carcinoma tissue by molecular hybridization. J Exp Pathol. 1992;6(1–2):55–64.

    PubMed  CAS  Google Scholar 

  11. Bast RC Jr, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19-9, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149(5):553–9.

    PubMed  Google Scholar 

  12. Dawood MY, Ratnam SS, Teoh ES. Serum estradiol-17 beta and serum human chorionic gonadotropin in patients with hydatidiform moles. Am J Obstet Gynecol. 1974;119(7):904–10.

    PubMed  CAS  Google Scholar 

  13. Yachnin S. The clinical significance of human alpha-fetoprotein. Ann Clin Lab Sci. 1978;8(2):84–90. Review.

    PubMed  CAS  Google Scholar 

  14. Beveridge RA. Review of clinical studies of CA 27.29 in breast cancer management. Int J Biol Markers. 1999;14(1):36–9. Review.

    PubMed  CAS  Google Scholar 

  15. Lehner R, Enomoto T, McGregor JA, Shroyer AL, Haugen BR, Pugazhenthi U, et al. Quantitative analysis of telomerase hTERT mRNA and telomerase activity in endometrioid adenocarcinoma and in normal endometrium. Gynecol Oncol. 2002;84(1):120–5.

    Article  PubMed  CAS  Google Scholar 

  16. Mylonas I, Matsingou C, Käufl SD, Brüning A. Inhibin/activin betaE-subunit in uterine endometrioid adenocarcinoma and endometrial cancer cell lines: from immunohistochemistry to clinical testing? Gynecol Oncol. 2011;122(1):132–40. Epub 2011 Apr 20.

    Article  PubMed  CAS  Google Scholar 

  17. Mylonas I. Inhibin-α subunit expression in uterine endometrioid adenocarcinomas and endometrial cancer cell lines: a potential prognostic factor. Int J Mol Med. 2011;27(3):309–18. doi:10.3892/ijmm.2010.586. Epub 2010 Dec 21.

    Article  PubMed  CAS  Google Scholar 

  18. Chang HL, Pahlavan N, Halpern EF, MacLaughlin DT. Serum Müllerian Inhibiting Substance/anti-Müllerian hormone levels in patients with adult granulosa cell tumors directly correlate with aggregate tumor mass as determined by pathology or radiology. Gynecol Oncol. 2009;114(1):57–60. Epub 2009 Apr 8.

    Article  PubMed  CAS  Google Scholar 

  19. Holden JA, Snow GW, Perkins SL, Jolles CJ, Kjeldsberg CR. Immunohistochemical staining for DNA topoisomerase II in frozen and formalin-fixed paraffin-embedded human tissues. Mod Pathol. 1994;7(8):829–34.

    PubMed  CAS  Google Scholar 

  20. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95(1):9–15.

    Article  PubMed  CAS  Google Scholar 

  21. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American society of clinical oncology. American society of clinical oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25(33):5287–312. Epub 2007 Oct 22. Review.

    Article  PubMed  CAS  Google Scholar 

  22. Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer—European group on tumor markers recommendations. Tumour Biol. 2005;26(6):281–93. Review.

    Article  PubMed  Google Scholar 

  23. Duffy MJ, Evoy D, McDermott EW. CA 15–3: uses and limitation as a biomarker for breast cancer. Clin Chim Acta. 2010;411(23–24):1869–74. Epub 2010 Sep 8. Review.

    Article  PubMed  CAS  Google Scholar 

  24. van Nagell J Jr, Donaldson ES, Wood EG, Goldenberg DM. The clinical significance of carcinoembryonic antigen in the plasma and tumors of patients with gynecologic malignancies. Cancer. 1978;42(3):1527–32. Review.

    Article  PubMed  Google Scholar 

  25. Fisher B, Redmond CK, Wickerham DL, Rockette HE, Brown A, Allegra J, et al. Relation of estrogen and/or progesterone receptor content of breast cancer to patient outcome following adjuvant chemotherapy. Breast Cancer Res Treat. 1983;3(4):355–64.

    Article  PubMed  CAS  Google Scholar 

  26. Syrjänen KJ, Kosma VM. Hormone receptor levels related to histological parameters of tumor-host relationships in female breast carcinoma. J Surg Oncol. 1982;21(1):49–53.

    Article  PubMed  Google Scholar 

  27. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707–12.

    Article  PubMed  CAS  Google Scholar 

  28. Bouchet C, Spyratos F, Martin PM, Hacène K, Gentile A, Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994;69(2):398–405.

    Article  PubMed  CAS  Google Scholar 

  29. Kim C, Paik S. Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol. 2010;7(6):340–7. Epub 2010 May 4. Review.

    Article  PubMed  CAS  Google Scholar 

  30. Kawauchi S, Furuya T, Ikemoto K, Nakao M, Yamamoto S, Oka M, et al. DNA copy number aberrations associated with aneuploidy and chromosomal instability in breast cancers. Oncol Rep. 2010;24(4):875–83.

    Article  PubMed  CAS  Google Scholar 

  31. Angelopopulou K, Diamandis EP, Sutherland DJA. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Can. 1994;58:480–7.

    Article  Google Scholar 

  32. Tandon AK, Clark GM, Chamness GC, et al. Cathepsin D and prognosis in breast cancer. N Eng J Med. 1990;322:239–331.

    Article  Google Scholar 

  33. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, et al. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009;8(7):1062–8. Epub 2009 Apr 10.

    Article  PubMed  CAS  Google Scholar 

  34. Goncalves A, Bertucci F. Clinical application of proteomics in breast cancer: state of the art and perspectives. Med Princ Pract. 2011;20(1):4–18. Epub 2010 Dec 13. Review.

    Article  PubMed  Google Scholar 

  35. Schwarzenbach H, Pantel K, Kemper B, Beeger C, Otterbach F, Kimmig R, et al. Comparative evaluation of cell-free tumor DNA in blood and disseminated tumor cells in bone marrow of patients with primary breast cancer. Breast Cancer Res. 2009;11(5):R71. Epub.

    Article  PubMed  Google Scholar 

  36. Lianidou ES, Markou A. Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem. 2011;57(9):1242–55.

    Article  PubMed  CAS  Google Scholar 

  37. Lu J, Chang KL. Practical immunohistochemistry in hematopathology: a review of useful antibodies for diagnosis. Adv Anat Pathol. 2011;18(2):133–51. Review.

    Article  PubMed  Google Scholar 

  38. Vaidyanathan K, Lakhotia S, Ravishankar HM, Tabassum U, Mukherjee G, Somsundaram K. BRCA1 and BRCA2 germline mutation analysis among indian women: identification of four novel mutations and high frequency occurrence of 185delAG mutation with independent origin. J Biosci. 2009;34(3):415–22.

    Article  PubMed  CAS  Google Scholar 

  39. Vaidyanathan K. Role of BRCA1/2 genes in hereditary ovarian cancer—IISc experience. Indian J Med Pediatr Oncol. 2007;27(1):21–2.

    Google Scholar 

  40. Vaidyanathan K, Ravi Shanker HM, Lakhotia S, Somasundaram K, Mukherjee G. Role of BRCA1 and BRCA2 genes in hereditary breast/ovarian cancer. Chin Med J. 2007;120(2):115–6.

    Google Scholar 

  41. Vaidyanathan K, Kumar P, Reddy CO, Deshmane V, Somasundaram K, Mukherjee G. ErbB-2 expression and its association with other biological parameters of breast cancer among Indian women. Indian J Cancer. 2010;47(1):8–15.

    Article  PubMed  CAS  Google Scholar 

  42. Gilligan TD, Seidenfeld J, Basch EM, Einhorn LH, Fancher T, Smith DC, et al. American society of clinical oncology. American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol. 2010;28(20):3388–404. Epub 2010 Jun 7.

    Article  PubMed  CAS  Google Scholar 

  43. Javadpour N. Multiple biochemical tumor markers in seminoma. A double-blind study. Cancer. 1983;52(5):887–9.

    Article  PubMed  CAS  Google Scholar 

  44. Ferro MA, Barnes I, Roberts JB, Smith PJ. Tumour markers in prostatic carcinoma. A comparison of prostate-specific antigen with acid phosphatase. Br J Urol. 1987;60(1):69–73.

    Article  PubMed  CAS  Google Scholar 

  45. Jorda M, Morales A, Ghorab Z, Fernandez G, Nadji M, Block N. Her2 expression in prostatic cancer: a comparison with mammary carcinoma. J Urol. 2002;168(4 Pt 1):1412–4.

    PubMed  Google Scholar 

  46. Fonseca GN, Srougi M, Leite KR, Nesrallah LJ, Ortiz V. The role of HER2/neu, BCL2, p53 genes and proliferating cell nuclear protein as molecular prognostic parameters in localized prostate carcinoma. Sao Paulo Med J. 2004;122(3):124–7. Epub 2004 Sep 16.

    Article  PubMed  Google Scholar 

  47. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3(94):94ra72.

    Article  PubMed  CAS  Google Scholar 

  48. Engstrom PF, Benson AB 3rd, Saltz L. National comprehensive cancer network. Colon cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2003;1(1):40–53.

    PubMed  Google Scholar 

  49. Bohanes P, Labonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in colorectal cancer. Semin Oncol. 2011;38(4):576–87.

    Article  PubMed  CAS  Google Scholar 

  50. Pino MS, Chung DC. Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol. 2011;5(3):385–99.

    Article  PubMed  Google Scholar 

  51. Kruszewski WJ, Rzepko R, Ciesielski M, Szefel J, Zieliński J, Szajewski M, et al. Expression of HER2 in colorectal cancer does not correlate with prognosis. Dis Markers. 2010;29(5):207–12.

    PubMed  Google Scholar 

  52. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Mäkelä O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol. 1984;37(2):218–22.

    Article  PubMed  CAS  Google Scholar 

  53. Khoo SK, Mackay IR. Carcinoembryonic antigen in serum in diseases of the liver and pancreas. J Clin Pathol. 1973;26(7):470–5.

    Article  PubMed  CAS  Google Scholar 

  54. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol. 2011;8(2):71–3. Review.

    Article  PubMed  CAS  Google Scholar 

  55. Veale D, Ashcroft T, Marsh C, Gibson GJ, Harris AL. Epidermal growth factor receptors in non-small cell lung cancer. Br J Cancer. 1987;55(5):513–6.

    Article  PubMed  CAS  Google Scholar 

  56. Pedersen MW, Meltorn M, Damstrup L, Poulsen HS. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol. 2001;12(6):745–60. Review.

    Article  PubMed  CAS  Google Scholar 

  57. Sudhoff HH, Schwarze HP, Winder D, Steinstraesser L, Görner M, Stanley M, et al. Evidence for a causal association for HPV in head and neck cancers. Eur Arch Otorhinolaryngol. 2011;268(11):1541–7.

    Article  PubMed  CAS  Google Scholar 

  58. Shivaraj G, Prakash BD, Sonal V, Shruthi K, Vinayak H, Avinash M. Thyroid function tests: a review. Eur Rev Med Pharmacol Sci. 2009;13(5):341–9. Review.

    PubMed  CAS  Google Scholar 

  59. Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med. 2011;135(5):569–77. Review.

    PubMed  CAS  Google Scholar 

  60. Marsh DJ, Gimm O. Multiple endocrine neoplasia: types 1 and 2. Adv Otorhinolaryngol. 2011;70:84–90. Epub 2011 Feb 24. Review.

    PubMed  Google Scholar 

  61. Bartram CR. bcr Rearrangement without juxtaposition of c-abl in chronic myelocytic leukemia. J Exp Med. 1985;162(6):2175–9.

    Article  PubMed  CAS  Google Scholar 

  62. Delgado J, Pratt G, Phillips N, Briones J, Fegan C, Nomdedeu J, et al. Beta2-microglobulin is a better predictor of treatment-free survival in patients with chronic lymphocytic leukaemia if adjusted according to glomerular filtration rate. Br J Haematol. 2009;145(6):801–5. Epub 2009 Apr 15.

    Article  PubMed  CAS  Google Scholar 

  63. Ankathil R, Stephen J, Vasudevan DM, Kusumakumary P, Pillai GR, Nair MK. Prognostic significance of karyotype analysis in children with acute lymphoblastic leukemia. Hematol Oncol. 1992;10(6):339–44.

    Article  PubMed  CAS  Google Scholar 

  64. Hsi ED, Yegappan S. Lymphoma immunophenotyping: a new era in paraffin-section immunohistochemistry. Adv Anat Pathol. 2001;8(4):218–39. Review.

    Article  PubMed  CAS  Google Scholar 

  65. Maha A, Gan GG, Koh CL. Phenotype and TCR-gamma gene rearrangements in a Malaysian cohort of T-cell leukaemia/lymphoma cases. Hematology. 2010;15(6):382–90.

    Article  PubMed  CAS  Google Scholar 

  66. Bosler DS, Douglas-Nikitin VK, Harris VN, Smith MD. Detection of T-regulatory cells has a potential role in the diagnosis of classical Hodgkin lymphoma. Cytometry B Clin Cytom. 2008;74(4):227–35.

    PubMed  Google Scholar 

  67. Budman LI, Kassouf W, Steinberg JR. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J. 2008;2(3):212–21.

    PubMed  Google Scholar 

  68. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res. 2011;17(8):2417–25. Epub 2011 Apr 12.

    Article  PubMed  CAS  Google Scholar 

  69. Kim DH, Oh SJ, Oh CA, Choi MG, Noh JH, Sohn TS et al. The relationships between perioperative CEA, CA 19-9, and CA 72-4 and recurrence in gastric cancer patients after curative radical gastrectomy. J Surg Oncol. 2011. doi:10.1002/jso.21919.

  70. Chua TC, Merrett ND. Clinicopathologic factors associated with HER2-Positive gastric cancer and its impact on survival outcomes—a systematic review. Int J Cancer. doi:10.1002/ijc.26292.

  71. Suresh K, Jayavardhanan KK, Vasudevan DM. Defective interleukin-2 R gene expression in gastric carcinoma patients. Immunol Invest. 1995;24(4):565–71.

    Article  PubMed  CAS  Google Scholar 

  72. Vasudevan DM, Vijayakumar T. Viruses in human oral cancers. J Exp Clin Cancer Res. 1998;17(1):27–31.

    PubMed  CAS  Google Scholar 

  73. Pillay M, Vasudevan DM, Rao CP, Vidya M. p53 expression in oral cancer: observations of a South Indian study. J Exp Clin Cancer Res. 2003;22(3):447–51.

    PubMed  CAS  Google Scholar 

  74. Vijayan KK, Remani P, Beevi VM, Ankathil R, Vijayakumar T, Rajendran R, et al. Tissue binding patterns of lectins in premalignant and malignant lesions of the oral cavity. J Exp Pathol. 1987;3(3):295–304.

    PubMed  CAS  Google Scholar 

  75. Ravindran A, Vijayakumar T, Sudha L, Remani P, Vasudevan DM, Stephen J, et al. Chromosome abnormalities in squamous cell carcinoma of the human oral cavity. Neoplasma. 1990;37(2):191–7.

    PubMed  CAS  Google Scholar 

  76. Perkins GL, Slater ED, Sanders GK, Prichard JG. Serum tumor markers. Am Fam Physician. 2003;68:1075–82.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biochemistry, Amrita Institute of Medical Science, Kochi, 682041, Kerala, India

    Kannan Vaidyanathan & D. M. Vasudevan

Authors
  1. Kannan Vaidyanathan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. M. Vasudevan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kannan Vaidyanathan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Vaidyanathan, K., Vasudevan, D.M. Organ Specific Tumor Markers: What’s New?. Ind J Clin Biochem 27, 110–120 (2012). https://doi.org/10.1007/s12291-011-0173-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12291-011-0173-8

Keywords

Search

Navigation